The MYC genes are the most frequently activated oncogenes in human tumors and are hence attractive therapeutic targets. MYCN amplification leads to poor clinical outcome in childhood neuroblastoma, yet strategies to modulate the function of MYCN do not exist. Here we show that 10058-F4, a characterized c-MYC/Max inhibitor, also targets the MYCN/Max interaction, leading to cell cycle arrest, apoptosis, and neuronal differentiation in MYCN-amplified neuroblastoma cells and to increased survival of MYCN transgenic mice. We also report the discovery that inhibition of MYC is accompanied by accumulation of intracellular lipid droplets in tumor cells as a direct consequence of mitochondrial dysfunction. This study expands on the current knowledge of how MYC proteins control the metabolic reprogramming of cancer cells, especially highlighting lipid metabolism and the respiratory chain as important pathways involved in neuroblastoma pathogenesis. Together our data support direct MYC inhibition as a promising strategy for the treatment of MYCdriven tumors.
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mitochondria | fatty acid oxidation | oxidative phosphorylation | small molecule | cancer therapy T he MYC proteins (here referring to c-MYC and MYCN) are helix-loop-helix leucine zipper transcriptional regulators that control a variety of normal cellular functions by forming specific DNA-binding heterodimers with the Max protein (1, 2) . Deregulated MYC expression is a key event for malignant transformation by inducing multiple tumor-promoting events, including uncontrolled cell proliferation, cell mass expansion, and genomic instability, and contributes to the genesis of a large number of human cancers (1) (2) (3) . Metabolic reprogramming is essential in cancer cells for adaptation to the tumor microenvironment and for maintenance of tumor growth (4, 5) . MYC is a potent regulator of these processes by inducing increased glycolysis and glutaminolysis (6, 7) and by stimulating mitochondrial biogenesis and function (8) (9) (10) . Several lines of experimental evidence support MYC as a therapeutic target (3, 6, 11, 12) . Its down-regulation is sufficient to cause tumor regression, mediated by cell growth arrest, apoptosis, senescence, and/or differentiation in MYC-driven animal models (13) , and systemic MYC inhibition in mice has been reported to cause minimal and reversible side effects for normal cells and tissues (14) .
Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system. In this malignancy, MYCN oncogene activation through amplification is an important hallmark of advanced tumor stage and poor prognosis, characterizing one subset of high-risk patients prone to resistant disease and progression despite intensive multimodal therapy (15) . Importantly, downregulation of MYCN expression results in apoptosis, decreased proliferation, and/or neuronal differentiation in NB cells in vitro (16, 17) . Consequently, MYCN is an attractive target for therapy in high-risk NB.
Small molecules inhibiting protein-protein interactions represent a challenging yet desirable strategy for cancer therapy. The low-molecular-weight compound 10058-F4 has been shown to bind c-MYC in vitro, to disrupt c-MYC/Max interaction, and to inhibit the growth of c-MYC-transformed cells (11, 18) but failed to elicit efficacy in vivo (19) . Here, we demonstrate 10058-F4 to target NB cells with high MYCN expression and to induce antitumorigenic responses in relevant experimental models of NB. We also show that inhibition of MYCN is accompanied by accumulation of intracellular lipid droplets in NB cells owing to mitochondrial dysfunction.
Results

10058-F4 Targets the MYCN/Max Interaction in NB Cells, Resulting
in Growth Inhibition and Apoptosis. On the basis of sequence similarity between MYCN and c-MYC, we addressed whether 10058-F4 could interfere with MYCN/Max dimerization. Indeed, MYCN/Max interaction was inhibited in situ after treatment of MYCN-amplified (MNA) NB cells with 10058-F4 ( Fig. 1 A and B) . Neither the total levels of MYCN (Fig. 1A) nor Max was affected at the early time point analyzed. These results were corroborated in a second MNA cell line in which less MYCN protein was coimmunoprecipitated with Max after 10058-F4-treatment (Fig. 1C) . As expected (18) , less c-MYC was also retrieved in Max immunoprecipitations from c-MYC-expressing p493-6 B cells after incubation with 10058-F4 compared with control (Fig. 1C) . Extended treatment of MNA NB cell lines revealed a concentration-dependent decrease in MYCN protein levels (Fig.  1D ), which was blocked by proteasome inhibition (Fig. S1A) , suggesting involvement of proteasome-mediated proteolysis in response to interference with the MYCN/Max interaction. We also observed decreased MYCN/Max and c-MYC/Max DNA binding after 10058-F4 treatment (Fig. 1E) , probably reflecting reduced total levels of MYCN (Fig. 1D ) and of c-MYC. Hence, 10058-F4 targets the MYCN/Max interaction, ultimately resulting in decreased MYCN levels in NB cells.
If 10058-F4 targets MYCN in addition to c-MYC, we would expect growth-suppressive effects in NB cells with high MYCN expression. Indeed, 10058-F4 induced both G1 arrest and apoptosis to a higher extent in MNA cell lines compared with non-MNA cells (Fig. 2 A and B) , and Tet21N cells with high MYCN expression were more sensitive to 10058-F4-induced apoptosis compared with low MYCN-expressing cells (Fig. S1B) . Furthermore, treatment of MNA NB cells with 10058-F4 decreased their capacity to grow in an anchorage-independent manner and inhibited cell migration (Fig. S1 C and D) . These data suggest that 10058-F4 targets NB cells that depend on maintained MYC expression.
10058-F4 Induces NB Cell Differentiation and TrkA Expression. MYCN suppresses neuronal differentiation, whereas MYCN inhibition in vitro results in differentiation of MNA NB cells (16, 20) . This led us to ask whether 10058-F4 has the capacity to induce differentiation in NB cells. Neurite outgrowth was evident after continuous incubation of two MNA cell lines with sublethal concentrations of 10058-F4 (Fig. 2C and Fig. S1E ). The neurotrophin receptor TrkA is a reliable genetic marker of differentiation and a strong predictor of a favorable prognosis in NB, and high expression in tumors correlates inversely with MNA (16, 17, 21) . Both TRKA mRNA and protein were up-regulated by 10058-F4 in the two differentiated MNA NB cell lines (Fig. 2D and Fig. S1F ).
Functional induction of the TrkA receptor by 10058-F4 was further supported because nerve growth factor, the high-affinity ligand of TrkA (16) , potentiated the differentiated morphology of 10058-F4-treated cells by increasing both the number and length of neurite protrusions (Fig. 2C) . Thus, 10058-F4 is sufficient to relieve MYCN-mediated suppression of NB cell differentiation.
10058-F4 Elicits Therapeutic Responses in NB Tumor Models. We next evaluated the therapeutic response in the preclinical TH-MYCN transgenic mouse model, which recapitulates human high-risk NB (22), and observed that treatment significantly prolonged the survival of tumor-bearing mice (Fig. 2E) . We also examined the response in a s.c. MNA NB xenograft model using highly aggressive SK-N-BE(2) cells. Although the effect of 10058-F4 on overall tumor growth was not significant (Fig. S1G) , there was a significant delay until the tumors increased two-, four-, or sixfold in volume (Fig. S1H) . Furthermore, immunohistochemistry staining revealed 41% more cleaved caspase-3 in sections from treated compared with control tumors, demonstrating that 10058-F4 induced apoptosis in the NB xenografts (Fig. S1 I and J) . Hence, in vivo effects can be achieved using a small molecule that targets the MYC/Max interaction.
MYC Inhibition Results in Lipid Accumulation in Tumor
Cells. An intriguing observation after 10058-F4 treatment was that vesiclelike particles not present in untreated cells accumulated over time throughout the cell cytoplasm. Staining of 10058-F4-treated MNA NB cells with Oil Red O revealed that the vesicles contained fat (Fig. 3A) . This finding was supported by transmission electron microscopy (Fig. 3B) . To assess whether the increase in lipid droplets could be attributed to direct targeting of MYCN we transfected MNA NB cells with MYCN-shRNA. A marked induction of lipid accumulation was indeed observed after MYCN down-regulation (Fig. 3 C and D) . Next we investigated the effect of the bromodomain inhibitor JQ1, recently shown to inhibit c-MYC transcription (23, 24). Strikingly, JQ1 decreased the MYCN levels, followed by formation of lipid droplets ( Additionally, we used isogenic rat embryonic fibroblast cell lines with different c-myc status to address whether this finding also applies to c-MYC down-regulation. Untreated HO15.19 c-myc null cells contained high amounts of stainable lipid droplets compared with the low levels present in parental TGR-1 and in c-myc overexpressing HOmyc3 cells (Fig. 3G) . As expected, treatment with 10058-F4 did not impact on the already high lipid content in the HO15.19 cells. However, a robust increase in lipids was observed in the TGR-1 cells and to an even greater extent in the HOmyc3 cells after 10058-F4-incubation (Fig. 3G) .
Lipids also accumulated in response to 10058-F4 treatment in additional tumor cell lines analyzed (Fig. S2A) . In contrast, treatment of primary, nontransformed human lung and dermal fibroblasts did not result in accumulated lipids (Fig. S2B) . Importantly, out of three cytotoxic drugs tested, only cisplatin treatment led to elevated levels of stainable lipids in NB cells at sublethal concentrations (Fig. S2C) . Whereas cisplatin did not affect proliferation, both etoposide and camptothecin induced arrest in the G2 phase of the cell cycle (Fig. S2D) , indicating that growth suppression per se does not lead to lipid accumulation. Finally, we observed that sections from 10058-F4-treated TH-MYCN tumors generally contained more fat droplets compared with those from vehicle-treated tumors (Fig. S2E) . Together, these findings demonstrate that inhibition of MYCN or c-MYC can result in accumulation of lipids in cells with elevated MYCregulated metabolism. (Table S1 and Datasets S1 and S2). Gene ontology (GO) predictions revealed a striking similarity in affected biological processes in response to both treatments (Fig.  4A) . Notably there was a robust impact of 10058-F4 on downstream MYC-targets. Ingenuity analysis of regulated canonical cell signaling pathways demonstrated that the same processes were consistently impaired in both conditions, with the greatest effect seen on cellular activities associated with MYC, including protein translation and mitochondrial functions ( Fig. 4B and Datasets S1 and S2). Importantly, Ingenuity analysis predicted MYCN and c-MYC to be the two most significantly affected transcription factors in response to both 10058-F4 as well as MYCN-shRNA (Fig. S3A) . The proteomic data were validated using immunoblotting (Fig. S3B) . Collectively, these data show that 10058-F4 targets MYC signaling in NB cells.
MYCN Inhibition Causes Respiratory Chain Impairment. To further dissect how 10058-F4 influences NB cell metabolism and consequently causes lipid accumulation, we compiled all proteins involved in respiration as well as carbohydrate, lipid, and amino acid metabolism found down-regulated in the two experimental settings (Tables S2 and S3 ). The majority of down-regulated metabolic proteins were those comprising the respiratory chain both in response to 10058-F4 and anti-MYCN shRNA ( Fig. 5A and Tables S2 and S3), suggesting that these changes caused the observed lipid accumulation. Interestingly, the levels of many enzymes involved in catalyzing β-oxidation of fatty acids as well as essential factors regulating the citric acid cycle and glycolysis were also reduced after 10058-F4 treatment. In addition, several enzymes involved in amino acid metabolism were affected (Fig. 5 A and B and Table S2 ). Approximately half of the metabolismrelated proteins down-regulated by 10058-F4 are reported MYCtarget genes (Table S2) .
Inhibition of Mitochondrial Respiratory Complexes and β-Oxidation
Induce Lipid Accumulation. Interference with fatty acid β-oxidation during continued cellular fatty acid import or synthesis can lead to accumulation of lipids in nonadipose cells (25-27), and our proteomic data demonstrated that 10058-F4 decreased the expression of essential enzymes regulating fatty acid oxidation (Fig. 5 A and B and Table S2 ). Together with the observed effect on the respiratory chain (Fig. S3C ), this suggests that alterations in the integrity of the respiratory chain in response to MYCN inhibition result in reduced capacity for oxidation of fatty acids in mitochondria. Increased lipid levels could indeed be observed in MNA NB cells after treatment with inhibitors of the respiratory chain as well as of β-oxidation, whereas two inhibitors of glycolysis did not affect the amount of lipid droplets (Fig. 5C ).
Conceivably, lipid accumulation in response to MYCN inhibition could also result from an imbalance in the decay time of MYCmediated processes, causing lipid synthesis to exceed growth demands. Hence, to investigate the possibility that continued fatty acid biosynthesis may contribute to the accumulation of lipids, we treated NB cells with 10058-F4 in combination with inhibitors of fatty acid synthesis. Treatment with the fatty acid synthase (FASN) inhibitor cerulenin (28) at sublethal concentrations did not impact on the lipid accumulation induced by 10058-F4 ( Fig. 5D and Fig. S2F ). In contrast, 5-(Tetradecyloxy)-2-furoic acid (TOFA), which inhibits acetyl CoA carboxylase (ACC) (29), although it may also stimulate β-oxidation because of decreased levels of malonyl-CoA (29-31), almost completely blocked the 10058-F4-induced fat droplet formation ( Fig. 5D and Fig. S2F ). We also addressed the possibility that previously synthesized lipids, which would have been used in various cellular processes during continued proliferation, may accumulate after growth suppression in response to MYC inhibition. Hence, we pretreated cells with cerulenin to inhibit lipid synthesis before the addition of 10058-F4. Nevertheless, pretreatment did not influence the 10058-F4-induced lipid accumulation (Fig. S2G ).
Together these results support reduced oxidation, rather than continued synthesis of fatty acids or accumulation of previously synthesized lipids, as the major cause of lipid droplet formation in response to 10058-F4 treatment. Two animals per treatment group were homozygous for the MYCN transgene, and the rest were heterozygous. The median number of days in treatment was 11 (n = 27) for control and 21 (n = 9) for 10058-F4-treated animals (P = 0.0303).
Given the fact that lipid accumulation occurred in response to inhibition of mitochondrial processes, we next assessed the longterm effects of 10058-F4 on the morphology of mitochondria in NB cells. Visualization with MitoTracker demonstrated that the networks of elongated mitochondrial structures seen in untreated MNA NB cells became shorter, and occasional ring-formed structures appeared in response to 10058-F4 (Fig. S3D ). Transmission electron microscopy revealed that mitochondria from treated cells appeared lighter and contained less elaborate cristae patterns, indicating loss of mitochondrial proteins (Fig. 5E ). These results are consistent with the observations that chronic depletion of c-MYC reduces mitochondrial mass, results in smaller and cristae-deficient mitochondria, and alters the dynamics of mitochondria fission and fusion, leading to reduced oxidative phosphorylation capacity (9, 10).
Finally we addressed the impact of affected metabolic proteins on NB patient survival using a clinical microarray data set representing 251 children (32). Gene expression corresponding to 20 of the metabolic proteins found down-regulated by 10058-F4 were available in this data set. Of these, 14 (70%) were found to positively correlate with high MYC pathway activity ( Fig. S4 A and B and Table S2 ) and were also significantly associated with reduced event-free (Table S2 ) and/or overall survival ( Fig. S4 A and C and Table S2 ). Taken together, our results strengthen the proposed function of MYC as an essential regulator of mitochondrial integrity in tumor cells. They also demonstrate that impairment of the respiratory chain by MYCN inhibition ultimately interferes with the oxidation of fatty acids, hence causing lipids to accumulate.
Discussion
Given the important role of deregulated MYC in conferring tumor aggressiveness, its therapeutic targeting represents a compelling approach in cancer research (3, 11) . Several groups have identified compounds that interfere with the interaction between c-MYC and Max (11) . However, clinical development of these compounds, including 10058-F4, is limited by their relatively low potency. To date no reports exist on the activity of any compound on the binding between MYCN and Max, nor has it been shown that in vivo efficacy can be achieved by any small molecule interfering with MYC/Max. Here we demonstrate that 10058-F4 targets the interaction between MYCN and Max and that treatment is sufficient to delay tumor growth in vivo in two NB models. Using a proteomic approach we revealed a robust down-regulation of proteins involved in MYC-regulated biological processes, and MYCN and c-MYC were predicted as the top two most inhibited transcription factors, showing the MYC specificity of this small molecule. Collectively our data clearly demonstrate that 10058-F4 inhibits MYCN signaling in NB cells, resulting in cell cycle arrest, apoptosis, and/or differentiation, as well as reduction of tumor growth in aggressive mouse models of NB.
By serendipity we found that lipid accumulation occurs in response to 10058-F4 treatment. Importantly, the use of several alternative strategies to modulate the function of MYC, including isogenic cell lines, the MYC-inhibitory small molecule JQ1, and MYCN-RNA interference, demonstrated this effect to be MYC specific. Our data furthermore indicated that 10058-F4 elicited a lipid response in NB tumors in vivo. In contrast, inhibition of physiological MYC levels seems insufficient to induce accumulation of lipids because 10058-F4 treatment of primary nontransformed fibroblasts did not lead to increased lipid levels.
Lipid metabolism is an emerging field in cancer research, and increased de novo lipid synthesis driven by misexpression of lipogenic enzymes such as FASN and ATP Citrate Lyase (ACLY), as well as enhanced fatty acid β-oxidation, have been implicated in different cancers (28, 29, 33, 34) . A possible link between MYC activity and lipid metabolism has not been thoroughly studied, and the few existing reports are contradictory, indicating that MYC can promote either fatty acid synthesis or fatty acid oxidation under different conditions (35, 36). Importantly, the metabolic reprogramming mediated by MYC during tumorigenesis was shown to depend on tissue type (37). Accumulation of cytoplasmic lipids was recently demonstrated to occur in cancer cells after knockdown of carnitine palmitoyltransferase 1C (CPT1c), the brain-specific isoform of the β-oxidation rate-limiting enzyme (27). Interestingly, high CPT1c expression has been reported in NB cells (38), suggesting that enhanced β-oxidation activity may be an important metabolic feature in this disease. Our data demonstrated that inhibition of CPT1 and of peroxisomal β-oxidation indeed led to lipid accumulation in NB cells. Furthermore, treatment with 10058-F4 resulted in reduced expression of several enzymes directly involved in regulating oxidation of fatty acids. Notably, high expression of some of these enzymes was found to correlate with high MYC pathway activity and to poor survival in NB patients. In addition, cisplatin, which caused increased levels of lipid droplets in NB cells, is to our knowledge the only cytotoxic drug of the three tested that has been shown to interfere with fatty acid oxidation (39).
The finding that inhibition of ACC using TOFA prevented 10058-F4-induced lipid accumulation suggests that continued lipogenesis may also play a role in causing unoxidized lipids to accumulate after MYCN inhibition. However, TOFA treatment results in decreased malonyl-CoA levels (30) and hence inhibits lipid synthesis, although it may simultaneously stimulate β-oxidation (29, 31). Together with the observation that lipid droplet formation by 10058-F4 occurred although FASN was inhibited using cerulenin, this suggests that continued lipid synthesis or accumulation of previously synthesized lipids, in the setting of a reduced proliferation rate, were not major causes of the observed lipid droplet formation. This conclusion was further supported by the finding that simply halting proliferation using sublethal concentrations of etoposide or camptothecin did not cause accumulation of lipids. Collectively, our data imply that inhibition of β-oxidation leads to lipid accumulation after MYCN inhibition and suggest that aggressive NB tumors use fatty acids as an energy source.
The view that tumor cells primarily adapt metabolically by means of the Warburg effect has been challenged by reports showing a link between enhanced oxidative phosphorylation and tumorigenesis (40, 41). Likely, both aerobic glycolysis and efficient mitochondrial metabolism are important to support the energetic and biosynthetic demands of cancer cells (42). Several groups have established MYC's role in supporting mitochondrial biogenesis (9, 10, 35, 43) , and the most obvious metabolic consequence observed in our proteomic analysis was the down-regulation of multiple subunits comprising all complexes of the respiratory chain. Importantly, inhibitors of different complexes of the respiratory chain all induced a robust lipid accumulation. Our data hence strengthen the emerging evidence for a defined role of MYC in stimulating oxidative phosphorylation, which may contribute to fulfill the bio-energetic demands of cancer cells by coordinating mitochondrial energy metabolism with cell proliferation and survival (8, 44) .
Together our findings establish proof of concept for the development toward direct MYC-inhibition as a future approach to inhibit tumor progression. Notably, these data further highlight the importance of alterations in lipid metabolism and the respiratory chain for MYCN-driven oncogenesis and demonstrate lipid accumulation to be a previously unknown consequence of inhibiting MYC. Our work also raises the question about possible implications of MYC in other human disorders, such as those contributing to the metabolic syndrome.
Materials and Methods
Detailed materials and methods are provided in SI Materials and Methods.
MYC/Max Interaction and DNA Binding. EMSA was performed as previously described (45), using protein lysates from cells treated with 10058-F4. For in vitro analysis of protein interaction between MYC/Max, extracts prepared from SK-N-BE(2) and p493-6 were incubated with 100 μM 10058-F4 or the corresponding volume of DMSO at 37°C for 30 min before immunoprecipitation of Max. Proximity ligation assay was performed using Duolink in situ PLA (Olink Bioscience).
Apoptosis and Cell Cycle Assay. Apoptosis and cell cycle analysis was done by propidium iodide staining followed by flow cytometric analysis.
Oil Red O Staining of Lipids. Cells grown on coverslips were fixed in 4% (wt/vol) paraformaldehyde before staining with Oil Red O solution in 60% (vol/vol) isopropanol. For staining of fat on frozen tumor sections (5-10 μm thick), 0.5% Oil Red O in propylene glycol was used according to Nova Ultra Special Stain Kits (IHC WORLD). For visualization, bright-field images were captured at 63× magnification using an Axiovert 40 CFL inverted fluorescence microscope (Zeiss) and Axiovision Rel. 4.8 software.
Animal Experiments. Mice received vehicle or 10058-F4 (25 mg/kg) i.p., daily. In TH-MYCN animals, treatment was initiated when mice had palpable tumors. Animals were followed until the tumor progression and/or general health warranted killing. For xenograft assays, SK-N-BE (2) (4, 5) . Transient transfection of cells with shRNA against MYCN (2) was done using lipofectamine (Invitrogen). MG115 and 10058-F4 were from Sigma-Aldrich. Metabolic inhibitors (Sigma-Aldrich) were used at the following concentrations: etomoxir sodium salt hydrate: 50 μM; thioridazine hydrochloride: 2.5 μM; rotenone: 40 nM; 2-thenoyltrifluoroacetone: 100 μM; antimycin A: 10 M; oligomycin: 1 μg/mL; dichloroacetic acid: 3 mM; bromopyruvic acid (3-BrPA): 10 μM; cerulenin: 5 or 10 μM; and 5-(Tetradecyloxy)-2-furoic acid (TOFA): 50 μM. Nerve growth factor (NGF) was from R&D Systems. JQ1 was a generous gift from J. Bradner, Dana Farber Institute (Boston, MA).
Western Blot Analysis. Whole-cell extracts were prepared using RIPA buffer (Sigma-Aldrich) supplemented with Halt Protease and Phosphatase Inhibitor Mixture (Thermo Scientific); 25-50 μg was resolved on SDS/PAGE and transferred to Amersham Hybond ECL membranes. The mouse monoclonal anti-c-MYC antibody (C-33) and anti-MYCN antibody (NCMII 100) were from Santa Cruz Biotechnology, the polyclonal antiTrkA antibody (catalog #06-574) from Millipore, and the Ab 143, which recognizes both c-MYC and MYCN, was a kind gift from R. Eisenman, Fred Hutchinson Cancer Center, Seattle, WA. Antibodies to topoisomerase (DNA) II alpha 170kDa (TOP2A) (HPA006458), ribosomal protein L27 (RPL27) (HPA002649), Aldolase A (ALDOA) (HPA004177), ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E (ATP5I) (HPA035010), and nucleophosmin (NPM) (HPA011384) were all purchased from Atlas Antibodies. Anti-GAPDH (Santa Cruz Biotechnology) or anti-β-actin (Sigma-Aldrich) antibodies were used as loading control. HRP-conjugated secondary antibodies were from GE Healthcare. Films were scanned in Geldoc XR (Bio-Rad) and quantified using Image Lab 3.0 (Bio-Rad).
Immunoprecipitation. For immunoprecipitation, Max antibody (C-17; Santa Cruz Biotechnology) was covalently bound to Protein G Sepharose 4 Fast Flow-beads (Amersham) and cross-linked using 40 mM dimethyl pimedilate in 0.1 M borate (pH 9). Extracts were prepared from SK-N-BE(2) and p493-6 cells using Frackelton lysis buffer. Extracts containing 500 μg protein were incubated with 200 μM 10058-F4 or the corresponding volume of DMSO at 37°C for 30 min. Equilibrated antibody-bound beads were incubated with treated extracts at 4°C for 4 h. After four washes with lysis buffer the beads were boiled in SDS sample buffer and analyzed by Western blot.
Proximity Ligation Assay and Immunofluoresecnce. The Duolink in situ proximity ligation assay (PLA) (Olink Bioscience) was used to detect interactions between MYCN and Max in cells. Cells were grown on coverslips and treated with 10058-F4 or DMSO at indicated concentrations and periods of time, fixed in 4% (vol/ vol) paraformaldehyde (PFA) and permeabilized with 0.5% Triton-X before performing the PLA assay according to the manufacturer's instructions. The antibodies NCM II 100 and C-17 (both from Santa Cruz Biotechnology) were used against MYCN and Max, respectively. To normalize the PLA signal, MYCN protein levels were assessed using immunofluorescence. Slides were incubated with a secondary fluorescently labeled α-mouse antibody (Alexa Fluor 568 goat anti-mouse; Invitrogen) after the PLA reaction was performed. ImageJ software was used for quantification of the number of PLA signals and for measuring the intensity of the MYCN immunofluorescence signal.
Electrophoretic Mobility Shift Assay. To assess the effect on DNA binding of the MYC-Max complex, EMSA was performed using protein lysates from cells treated in culture with 10058-F4. Fifteen micrograms of protein from SK-N-BE(2) or p493-6 cells was incubated for 30 min with sonicated salmon sperm DNA, antibodies to identify relevant bands by super shift, and drugs for the in vitro experiments at 25°C. This initial incubation was followed by 30 min incubation with [γ32P]-ATP end-labeled (5′-TCAGACCACGTGGTCGGG) probe at 25°C. The DNAprotein complexes were then separated on 5.5% polyacrylamide gels in 25 mM Tris base, 20 mM boric acid, and 0.5 mM EDTA at 4°C, dried, and visualized on a phosphoimager. Specific bands were identified using the following antibodies for supershifts: N262 (c-MYC), NCM II 100 (MYCN), and C-17 (Max), all from Santa Cruz Biotechnology.
Colony Formation Assay in Soft Agar. SK-N-BE(2) cells dissociated into single-cell suspension in 0.4% SeaPlaque agarose (Cambrex BioScience-Rockland) were seeded on top of solidified 0.6% agarose base layers. One hour later the gels were covered with medium containing DMSO or 10058-F4. Medium was thereafter changed every 3-4 d for up to 2 weeks when the experiment was terminated, and living cells in colonies were visualized using 100 μg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent (Calbiochem).
Cell Migration Assay. SK-N-BE(2) cells previously treated for 48 h with DMSO or 10058-F4 were resuspended in serum-free medium into single-cell suspension before being seeded into cell culture inserts of Boyden migration chambers (Transwell 24-well 8-μm polycarbonate filter assay system; Corning). Cells were allowed to migrate for 24 h through the 8-μm pores toward serum-containing medium [10% (vol/vol)], serving as chemoattractant in the bottom wells. Nonmigrated cells on top of the membranes were gently scraped off using a cotton tip, before being fixed in 4% PFA for 15 min and washed in PBS. Filters were removed from cell culture inserts using a scalpel and mounted onto object slides before staining with DAPI (Vectashield). Migrated cells were counted using an Axiovert 40 CFL inverted fluorescence microscope (Zeiss) and Axiovision Rel. 4.8 software. Duplicate or triplicate membranes were used per experimental point to calculate the average number of migrated cells in each experiment. For each membrane, three fields with cells (40× magnification) were manually counted and summed together.
Apoptosis Assays. 10058-F4-induced apoptosis was scored by quantifying the subG1 fraction of cells. Treated cells were fixed in 70% (vol/vol) ice-cold methanol and stored at −20°C. Cells were stained with propidium iodide (PI) solution (5 μg/mL PI and 25 μg/mL RNaseA in PBS) for 30 min at 37°C and analyzed in a FACScan flow cytometer (Becton Dickinson). Apoptotic cells were identified within the PI-stained population by virtue of exhibiting an apparent subdiploid DNA content.
Quantitative Real-Time PCR. Quantitative real-time PCR was performed as previously described (6) . Primers were designed using Primer Express software (Applied Biosystems). YWHAZ was used as reference gene.
Mouse Experiments. All animal experiments were in accordance with the Animal Protection Law (SFS1988:534), the Animal Protection Regulation (SFS 1988:539), and the Regulation for the Swedish National Board for Laboratory Animals (SFS1988:541) and approved by the Stockholm regional ethics committee for animal research.
Transgenic mice (7) were obtained from the Mouse Model of Human Cancer Consortium as an N16 backcross to the 129 × 1/SvJ background. Tumor development was monitored by abdominal palpations two to three times weekly. Animals that developed abdominal tumors at 35-70 d after birth were used. After confirmed tumor development, animals were randomized to receive either no treatment or 10058-F4 (25 mg/kg i.p, n = 9, daily for 2 weeks, thereafter three times weekly). The animals were followed until the tumor progression and/or general health warranted sacrifice.
For xenograft experiments 20 × 10 6 SK-N-BE(2) cells were engrafted s.c. onto 5-week-old female NMRI nude mice. After establishing tumors (0.2 mL), the animals were randomized to either no treatment (n = 11) or 10058-F4 (25 mg/kg daily i.p., n = 8). The tumor volume calculated as (width) 2 × length × 0.44, was measured daily. The body weight and general appearance was followed, and the mice were killed 10 d after randomization. The tumor volume index (TVI) was calculated as the measured tumor volume on each day of treatment divided by the starting volume.
Immunohistochemistry. For immunohistochemistry analysis, sections were deparaffinized, rehydrated, and subjected to hightemperature antigen retrieval. Endogenous peroxidase activity was eliminated by incubation with 30% (vol/vol) H 2 O 2. Primary antibody mouse monoclonal anti-activated caspase-3 (Cell Signaling) was used followed by secondary biotinylated rabbit anti-mouse antibody (DAKO) and developed using DAB reagents (Vector Laboratories). Counterstaining was done using Mayer's hematoxylin. Images were collected with an Axiovert 40 CFL inverted fluorescence microscope (Zeiss) and Axiovision Rel. 4.8 software. For quantification of apoptotic cells, four pictures of each of five tumors per group were taken, covering the areas containing the highest number of apoptotic cells. The average number of apoptotic cells per tumor section was calculated in vehicle compared with 10058-F4-treated tumors.
Mitotracker Staining. Mitochondria of treated cells were visualized by staining with 100 nM Mitotracker Red CMXRos (Invitrogen) in cell culture medium before the cells were fixed in formaldehyde and mounted for microscopic evaluation. Image acquisition was done at 63× magnification using an Axiovert 40 CFL inverted fluorescence microscope (Zeiss) and Axiovision Rel. 4.8 software.
Transmission Electron Microscopy. Electron micrographic pictures were obtained as described previously (8) . Briefly, cells were fixed [2.5% (wt/vol) glutaraldehyde in 0.1 M phosphate buffer, pH 7.4] at room temperature for 30 min, before being scraped off and transferred to Eppendorf tubes for further fixation and storage at 4°C. Cells were next rinsed in 0.1 M phosphate buffer and centrifuged. Pellets were postfixed in 2% (wt/vol) osmium tetroxide in 0.1 M phosphate buffer (pH 7.4) at 4°C for 2 h, dehydrated in ethanol followed by acetone, and embedded in LX-112 (Ladd). Ultrathin sections (∼40-50 nm) were cut using a Leica EM UC 6 ultramicrotome (Leica). Sections were contrasted with uranyl acetate followed by lead citrate and examined in a Tecnai 12 Spirit Bio TWIN transmission electron microscope (FEI) at 100 kV. Digital images were taken using a Veleta camera (Olympus Soft Imaging Solutions). . The homogenates were centrifuged at 14,000 × g at 4°C, for 10 min. Obtained supernatants were centrifuged at 100,000 × g at 4°C for 1 h to separate soluble proteins. Remaining pellets were dissolved in 500 μL of 2.5 M NaBr for 45 min on ice on a shaker, followed by centrifugation at 100,000 × g at 4°C for 1 h. The supernatants containing membrane-associated proteins (MAPs), and pellets containing microsomal proteins were stored at −20°C until further analysis. Digestion and iTRAQ labeling. Proteins from all three fractions were precipitated with chloroform/methanol as described in ref. 10 . The precipitates were solubilized in 100 μL of 10 mM Hepes buffer (pH 8.0) containing 0.1% SDS. The protein concentrations were measured using NanoDrop (Thermo Scientific). Twenty micrograms of protein from each sample were reduced using DTT (5 mM, at 56°C for 30 min) followed by alkylation by iodoacetamide (0.015 M, in darkness at room temperature for 30 min). Proteins were digested overnight at 37°C using trypsin (modified sequencing grade; Promega) 1:50 enzyme:substrate. Obtained peptides were labeled in duplicate by the 8-plex iTRAQ kit (Applied Biosystems) according to the manufacturer's instruction. The eluate was dried in a speed-vac and resuspended in 10 μL 3% acetonitrile and 0.1% formic acid before MS/MS analysis. MS analysis. LC-MS/MS was performed on a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo Fischer Scientific) coupled online to an Agilent HPLC 1200 system (Agilent Technologies). Samples were trapped on Zorbax 300SB-C18, 5 μm, 5 × 0.3 mm (Agilent Technologies) and separated on a NTCC-360/100-5-153 C18 column (Nikkyo Technos) coupled to the nano electrospray ionization source of the Orbitrap Velos instrument. The peptides were eluted using a 120-min gradient from 2% to 40% B [H 2 O/ ACN/Formic Acid 5%/95%/0.1% (vol/vol/vol)] at a flow of 0.4 μL/min. Acquisition was performed in ∼3.5-s scan cycles with initial single full-scan MS at 30,000 resolution and subsequent two stages of data-dependent tandem MS (centroid mode). From the full-scan MS the top five ions were selected for collision induced dissociation (CID, at 35% of energy) with detection in the ion trap (ITMS), and for high energy collision dissociation (HCD, at 50% energy) with detection in the orbitrap (FTMS). Precursors were isolated with a 2 m/z width and 60 s duration for the dynamic exclusion. Data analysis. Peptide and protein identification was performed by Mascot 2.2 (Matrix Science) using Proteome Discoverer 1.2 (Thermo Fischer Scientific) against International Protein Index (IPI) human target decoy (update 2011.07.06) protein sequence database. Searches were performed with trypsin specificity, and one missed cleavage was allowed. A precursor mass tolerance was set at 10 ppm, and a fragment mass tolerance was set at 0.02 Da for HCD-FTMS and 0.8 Da for CID-ITMS. Carbamidomethylation and iTRAQ-8plex on lysines and N terminals were chosen as a fixed modification, whereas oxidation of methionine was set as variable modification. Quantification of iTRAQ-8plex reporter ions was performed using Proteome Discoverer. For quantification all peptides were selected using a false discovery rate of <1%. Pathway analysis. Pathway analysis was performed using Ingenuity System Pathway Analysis software using the proteins detected in the proteomic analysis as input. Proteins were analyzed in a systematic way applying known protein-proteins interactions to determine the most significant interaction networks, global pathways, and protein functions, ranked by a score. Gene Ontology annotation comparison for the identified proteins was performed using the PANTHER classification system (http://www2.pantherdb.org/tools/), a resource that classifies the proteins by molecular function, biological process, and cellular component.
Neuroblastoma Patient Gene Expression Data Sets. A publicly available neuroblastoma (NB) patient (n = 251) gene expression dataset (11) (accession no. E-TABM-38; www.ebi.ac.uk) was used. Survival analyses based on expression above or below median were done for each gene. Gene expression comparison was done between quartile and median groups on the basis of MYC pathway activity score as defined in ref. 12 .
Statistics. Two-tailed Student t test was used for comparisons between two groups. ANOVA was used for comparisons between three or more groups. Comparison of survival between groups was done using a log-rank test (Mantle-Cox). The Mann-Whitney test was used for xenograft TVI. P values <0.05 were considered significant. Table shows proteins involved in the regulation of indicated metabolic pathways. Proteins were manually collected from the total list of affected proteins in response to 10058-F4-treatment, generated from the LC-MS/MS-based proteomic analysis (Dataset S1). Blank rows indicate proteins for which no gene expression data were available. NS = no significance. Table shows proteins involved in the regulation of indicated metabolic pathways. Proteins were manually collected from the total list of affected proteins after MYCN-shRNA induction, generated from the LC-MS/MS-based proteomic analysis (Dataset S2).
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